Extensive studies have demonstrated that EIF5A2 participates in the proliferation, migration, invasion and chemotherapeutic resistance of hepatocellular carcinoma, esophageal cancer, gastric cancer, melanoma, etc. [20–23]. Here, EIF5A2 is linked to gastric cancer.